Morepen Laboratories

Morepen Laboratories reported a 31% year-on-year decline in consolidated net profit for the March 2025 quarter, posting Rs. 20 crore compared to Rs. 29 crore in the same period last year. Despite the quarterly profit slip, annual performance painted a more optimistic picture, with net profit rising to Rs. 118 crore in FY25, up from Rs. 97 crore in FY24. The company’s revenue grew steadily, reflecting operational strength.

Pharmaceutical company Morepen Laboratories has unveiled a bold expansion blueprint aimed at significantly scaling its domestic formulations business. The firm plans to onboard over 1,000 medical representatives over the next three years, with 200 additions slated for FY26 alone, in an effort to penetrate deeper into both urban and rural markets. With its formulations division currently generating Rs. 325 crore, Morepen aims to grow this figure to Rs. 1,000 crore within five years. This strategy aligns with the company’s broader vision to capture a larger share of India’s Rs.

Pharmaceutical company Morepen Laboratories has unveiled a bold expansion blueprint aimed at significantly scaling its domestic formulations business. The firm plans to onboard over 1,000 medical representatives over the next three years, with 200 additions slated for FY26 alone, in an effort to penetrate deeper into both urban and rural markets. With its formulations division currently generating Rs. 325 crore, Morepen aims to grow this figure to Rs. 1,000 crore within five years. This strategy aligns with the company’s broader vision to capture a larger share of India’s Rs.